Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-08-18Clinical Trial Update: Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients [Phase 4]
A Phase 4 clinical trial by Alcon Research evaluated corneal structures in symptomatic allergic conjunctivitis patients using confocal analy…
-
FDA label_change · 2014-08-12FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for LASTACAFT (alcaftadine) by Allergan, Inc., resulting in a labeling change following the suppleme…
-
CLINICAL_TRIALS trial_result · 2014-08-11Clinical Trial Update: Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of an ophthalmic solution in patients with allergic conjunctivitis. The results we…
-
CLINICAL_TRIALS trial_result · 2014-08-04Clinical Trial Update: An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis [Phase 3]
An open-label, long-term Phase 3 study evaluating AL-4943A ophthalmic solution, 0.2%, in allergic conjunctivitis has completed.
-
CLINICAL_TRIALS trial_result · 2014-07-31Clinical Trial Update: Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects [Phase 3]
Phase 3 trial evaluating olopatadine hydrochloride ophthalmic solution versus vehicle in Japanese subjects with acute allergic conjunctiviti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-07-25FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for Lastacaft (alcaftadine).
-
CLINICAL_TRIALS trial_result · 2014-07-17Clinical Trial Update: AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation [Phase 2]
Alcon Research completed a Phase 2 clinical trial evaluating AL-38583 Ophthalmic Solution for allergic conjunctivitis with inflammation.
-
CLINICAL_TRIALS trial_result · 2014-07-14Clinical Trial Update: Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) [Phase 2, Phase 3]
Completed Phase 2/3 trial evaluating the efficacy and long-term safety of a ragweed pollen sublingual tablet in adults with ragweed-induced …
-
CLINICAL_TRIALS trial_result · 2014-07-11Clinical Trial Update: A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) [Phase 2]
This document reports the completion of a Phase 2 single-center clinical trial for moderate to severe allergic conjunctivitis using EBI-005-…
-
CLINICAL_TRIALS trial_result · 2014-07-03Clinical Trial Update: Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) [Phase 2, Phase 3]
Clinical trial update reporting efficacy and long-term safety of a ragweed sublingual immunotherapy tablet (SCH 39641) in adults with ragwee…
-
FDA approval · 2014-06-23FDA Approved: NAPHCON A — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for NAPHCON A (naphazoline hydrochloride and pheniramine maleate) from Alcon Laboratories, Inc.
-
CLINICAL_TRIALS trial_result · 2014-05-23Clinical Trial Update: Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) [Phase 2]
Phase 2 safety study of a ragweed pollen immunotherapy tablet in adults aged 50 and older (Study P06081) has completed, with results posted …
-
CLINICAL_TRIALS trial_result · 2014-04-29Clinical Trial Update: Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
A completed Korean trial evaluating the safety and efficacy of Relestat Ophthalmic Solution 0.05% for allergic conjunctivitis, with results …
-
CLINICAL_TRIALS trial_result · 2014-02-28Clinical Trial Update: A Six-Week Safety Study of an Investigational Ophthalmic Solution [Phase 3]
A Phase 3 six-week safety study of an investigational ophthalmic solution for allergic conjunctivitis has completed and results were posted.…
-
FDA approval · 2014-02-19FDA Approved: KETOTIFEN FUMARATE OPHTHALMIC SOLUTION — Supplemental Application (Sentiss Pharmaceuticals LLC)
FDA approved a supplemental application for Ketotifen Fumarate Ophthalmic Solution from Sentiss Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: AGN-229666 for the Treatment of Allergic Conjunctivitis [Phase 2]
Phase 2 clinical trial of AGN-229666 for allergic conjunctivitis completed; results were posted in February 2014.
-
CLINICAL_TRIALS trial_result · 2014-01-14Clinical Trial Update: A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis [Phase 4]
Phase 4 study comparing Lastacaft (olopatadine) to Pataday (olopatadine) and placebo for efficacy in acute allergic conjunctivitis; results …
-
CLINICAL_TRIALS trial_result · 2014-01-09Clinical Trial Update: Comparing Patient Satisfaction With Pataday or Bepreve [NA]
A completed clinical trial comparing patient satisfaction with Pataday (olopatadine) versus Bepreve (olopatadine) for eye allergies.
-
CLINICAL_TRIALS trial_result · 2013-11-08Clinical Trial Update: Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation [Phase 3]
A Phase 3 trial evaluating a high-dose sublingual grass pollen preparation shows efficacy and safety data in allergic rhinitis and allergic …
-
FDA approval · 2013-10-09FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for Loteprednol etabonate (Lotemax) by Bausch & Lomb Americas Inc., approving changes to the product…
-
FDA approval · 2013-09-12FDA Approved: PATADAY TWICE A DAY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Twice a Day Relief (olopatadine hydrochloride) from Alcon Laboratories, expanding labeli…
-
CLINICAL_TRIALS trial_result · 2013-09-10Clinical Trial Update: A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) [Phase 3]
Phase 3 trial evaluating SCH 697243 for grass pollen–related allergic rhinitis with allergic conjunctivitis, with or without asthma; results…
-
CLINICAL_TRIALS trial_result · 2013-07-18Clinical Trial Update: An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis [Phase 3]
Phase 3 trial assessing onset and duration of AKF-1 Ophthalmic Solution for acute allergic conjunctivitis has completed. The snippet does no…
-
CLINICAL_TRIALS trial_result · 2013-06-17Clinical Trial Update: The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial investigates whether the pollen season influences reactions to subcutaneous allergen immunotherapy in patie…
-
CLINICAL_TRIALS research · 2013-05-30Clinical Trial Update: Ocular Allergy Treatment Practical Impact Trial [Phase 4]
A Phase 4 clinical trial update for an ocular allergy treatment affecting allergic conjunctivitis and rhinoconjunctivitis; the trial status …